Business Context and Reporting Period
MEDIROM Healthcare Technologies Inc., a Japanese foreign private issuer, furnished this Form 6-K for December 2022. The filing reports a proposed convertible bond financing and related capital alliance with Kufu Company Inc.
Key Financial and Capital Markets Terms
- Principal amount: JPY 500 million.
- Expected closing: December 28, 2022, subject to customary and specified conditions precedent.
- Interest: 5.0% per annum, payable June 30, 2023 and semi-annually thereafter.
- Maturity: December 28, 2027, unless earlier redeemed or converted.
- Security: Unsecured convertible corporate bonds with share options.
- Conversion: At the bondholder’s option from six months after closing through maturity. The conversion price is based on 95% of the one-month average Nasdaq Capital Market trading price of the company’s ADSs before December 9, 2022, subject to customary adjustments.
- Gross proceeds: Expected to be JPY 500 million. The filing does not provide a clear amount for transaction expenses or net proceeds.
- Use of proceeds: Continued development of MOTHER Bracelet®, analysis of related data, and other purposes to be agreed with the bondholder. The company has not determined the specific allocation.
Material Changes and Strategic Arrangements
- The company entered into a purchase agreement and indenture with Kufu Company Inc. for the proposed bond issuance.
- The parties also entered into a Capital Alliance Agreement, effective at closing, to jointly evaluate opportunities involving MEDIROM’s relaxation salon business and MOTHER Bracelet®.
- The alliance may lead to a separate strategic partnership agreement, but neither party is obligated to enter into one.
- Kufu will receive certain anti-dilution protections, board observer rights, and information and access rights.
- The filing does not provide comparative revenue, earnings, cash flow, margin, debt, or liquidity figures.
Outlook, Risks, Contingencies, and Unusual Items
- Closing is conditioned on, among other matters, an extension of specified exclusivity provisions under the company’s agreement with Matrix Industries, Inc. and timely public disclosure of interim financial results for the six months ended June 30, 2022.
- The bondholder may require redemption after the six-month conversion start date and may have early redemption or conversion rights upon events including Nasdaq delisting, reporting delinquency, bankruptcy, insolvency, or consecutive operating losses for the years ending December 31, 2022 and 2023.
- Upon certain continuing events of default, all outstanding principal and accrued interest may become immediately due and payable.
- Conversion of the bonds could dilute existing shareholders. The Capital Alliance Agreement also provides anti-dilution protections to the bondholder in connection with certain new share issuances.
- The bonds and securities issuable upon conversion were offered outside the United States under Regulation S and were not registered under the Securities Act.
- The filing contains no formal financial guidance or quantified operating outlook.
Important Facts for Investors to Verify
- Whether the proposed bond issuance closed on December 28, 2022 and whether all closing conditions were satisfied.
- The final number of shares issuable upon conversion and the resulting potential dilution.
- The applicable conversion price based on the specified ADS trading-price calculation.
- The company’s ability to fund 5.0% annual interest payments and repay or refinance the JPY 500 million principal at maturity.
- The company’s interim financial results for the six months ended June 30, 2022 and operating performance for 2022 and 2023.
- The detailed terms, covenants, anti-dilution provisions, default triggers, and strategic rights contained in the attached purchase agreement, indenture, and Capital Alliance Agreement.